Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25867739 | 0.92 | CHRNA7 (0.35) | OPRD1SIGMAR1CHRNA7AVPR1A | |
| SCHEMBL31515349 | 0.86 | KDM1A (0.40) | OPRD1SIGMAR1 | |
| SCHEMBL25866229 | 0.85 | BRD4 (0.34) | OPRD1 | |
| SCHEMBL30954699 | 0.83 | KDM1A (0.38) | OPRD1SIGMAR1 | |
| SCHEMBL11834433 | 0.81 | AVPR1A (0.45) | SIGMAR1AVPR1A | |
| SCHEMBL30954718 | 0.80 | LMNA (0.41) | OPRD1AVPR1A | |
| SCHEMBL17586442 | 0.80 | CTSC (0.40) | OPRD1SIGMAR1 | |
| SCHEMBL30954707 | 0.79 | BACE1 (0.39) | OPRD1 | |
| SCHEMBL18373201 | 0.79 | HTR2C (0.40) | SIGMAR1 | |
| SCHEMBL6919513 | 0.78 | SIGMAR1 (0.57) | OPRD1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023134656-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | 上海壹典医药科技开发有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-RE47636-E1 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-08 | — | — | US | disclosed |
| EP-3191487-B1 | SPIROCYCLIC INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3511331-A1 | SPIROCYCLIC INHIBITORS OF CATHEPSIN C | Boehringer Ingelheim International GmbH (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-9879026-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879026-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-16 | — | — | US | disclosed |
| US-9540373-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9540373-B2 | Substituted spirocycles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20160075704-A1 | NOVEL SUBSTITUTED SPIROCYCLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075704-A1 | NOVEL SUBSTITUTED SPIROCYCLES | CTSC, CTSE, CTSS | OPRD1 1610/4885SIGMAR1 2679/4885CHRNA7 4405/4885 |
| US-20170073352-A1 | NOVEL SUBSTITUTED SPIROCYCLES | CTSC, CTSE, CTSS | OPRD1 1610/4885SIGMAR1 2679/4885CHRNA7 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.